Innovative Spring Sees Three Groundbreaking Cardiovascular Procedures Performed by AdventHealth Physicians

Dr. Mark Steiner, an interventional cardiologist, conducted the first commercial renal denervation procedure in Central Florida.
Dr. Mark Steiner performs the first commercial renal denervation procedure in Central Florida. This innovative treatment radiofrequency on nerves in the kidney to manage hypertension.

In a remarkable season of medical innovation, physicians with the AdventHealth Heart, Lung and Vascular Institute performed three groundbreaking procedures, marking significant advancements in patient care. These “firsts” represent a leap forward in the treatment of cardiovascular conditions for residents of Central Florida.

“Being first means we can offer our community access to leading treatments that may not be available elsewhere,” said Gordon Wesley vice president of the institute, who emphasized the significance of being at the forefront of medical and technological advancements. “This not only enhances patient outcomes but also attracts top talent and fosters clinical richness in the area, ultimately increasing access to care for our communities.”

Dr. Rodrigo Do Lago (middle), Dr. Jorge Suarez (second from left) and Dr. Nipun Arora (not shown) with team who performed first in Central Florida Abbott Navitor TAVR procedure on March 13, 2024.
Dr. Rodrigo Do Lago (middle), Dr. Jorge Suarez (second from left) and Dr. Nipun Arora (not shown) with team who performed first in Central Florida Abbott Navitor TAVR procedure on March 13, 2024.

On March 13, Dr. Nipun Arora, an interventional cardiologist, along with colleagues Dr. Rodrigo Do Lago and Dr. Jorge Suarez, performed the first-in-Central Florida Navitor Transcatheter Aortic Valve Replacement (TAVR) procedure. This minimally invasive procedure replaces the need for open-heart surgery, ultimately reducing recovery time. It treats aortic valve stenosis by replacing a narrow valve in the heart with a new one. This new technique not only ensures successful valve replacement but also holds promise for future heart surgeries.

Dr. Naushad Shaik with the AdventHealth team who performed the first-in-Central Florida Pulse Field Ablation (PFA) procedure on March 14, 2024.
Dr. Naushad Shaik (dark green scrubs, back left) with the AdventHealth team who performed the first-in-Central Florida Pulse Field Ablation (PFA) procedure on March 14, 2024.

The following day, on March 14, Dr. Naushad Shaik, electrophysiologist and EP medical director, led the inaugural Pulse Field Ablation (PFA) procedure in Central Florida. PFA is a promising new treatment for atrial fibrillation (AFib) patients. It’s a safer, more efficient approach than traditional methods that use heat, which can inadvertently damage surrounding tissues. PFA delivers short-duration electrical pulses to the cardiac tissue. The energy from the pulses kills the cells in the tissue causing the irregular heart rate and rhythm, therefore restoring the heart to a more normal condition.

Dr. Mark Steiner and the AdventHealth team perform the first commercial renal denervation procedure in the Central Florida market on May 21, 2024.
Dr. Mark Steiner (middle) and the AdventHealth team perform the first commercial renal denervation procedure in the Central Florida market on May 21, 2024.

Rounding out the trifecta, on May 21, Dr. Mark Steiner, an interventional cardiologist, conducted the first commercial renal denervation procedure in Central Florida. This innovative treatment targets patients with high blood pressure who do not respond to medication alone. High blood pressure affects nearly half of all Americans and can lead to serious health complications if left uncontrolled. This procedure uses radiofrequency on nerves in the kidney, which can cause hypertension. This offers a minimally invasive solution for managing a prevalent condition that can improve the quality of life for countless patients.

Gordon Wesley new headshot Spring 2024
Gordon Wesley is the vice president of the AdventHealth Heart, Lung and Vascular Institute.

“It is very rare we are able to do three, new technologically advanced procedures within weeks of each other,” said Wesley. “This is a testament to the collaboration with many on our team as well as the innovation happening at AdventHealth. We’ve become a destination for both experts and partners to leverage technology and knowledge simultaneously to advance patient care for our communities.”

Wesley adds that part of advancing patient care also means expanding care into new areas of the community to include an extension of the structural heart program at AdventHealth Celebration to include the TAVR program this month.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma

AdventHealth Clinical Research Unit (CRU) Executive Director and Medical Director of Genitourinary Oncology Guru Sonpavde, MD, co-authored an article on the AMBASSADOR Phase III clinical trial results...

Read Article about "New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma"
View More Articles